Menten AI

Menten AI develops MAUD 1.0 (Multi-parametric AI for Unbiased Design), a platform for de novo design of cyclic peptide macrocycles aimed at drug targets that are difficult to reach with small molecules and biologics, including protein-protein interfaces. The platform is used in preclinical discovery, and the company partners with pharmaceutical companies on such programs.

MAUD 1.0 combines generative AI, physics-based modeling, and quantum simulations. Its workflow includes Target Modeling, which analyzes a target protein structure to identify binding sites; a Molecular Engine that performs iterative multi-parameter design cycles covering backbone design, sequence design with natural and unnatural amino acids, and design ranking; and Hit/Lead Optimization for in silico fine-tuning of properties such as potency, stability, and permeability. Applications include oral peptides, cell-permeable peptides targeting intracellular proteins, molecular glues and bispecifics, and computational structure-based optimization.

Menten AI works with pharmaceutical companies on preclinical discovery and publishes peer-reviewed research. The pages describe partnership-based engagement rather than self-service plans, seats, or usage tiers.